Zobrazeno 1 - 10
of 53
pro vyhledávání: '"Marie Laure Risse"'
Autor:
Mehmut TURGUT, Roman HAJEK, Tomas JELÍNEK, Philippe MOREAU, Thomas MARTIN, Ludek POUR, Gabor MIKALA, Argiris SYMEONIDIS, Sara BRINGHEN, Andreea RAWLINGS, Marie Laure RISSE, Helgi VAN DE VELDE, Ivan SPICKA
Publikováno v:
Hematology, Transfusion and Cell Therapy, Vol 43, Iss , Pp S18- (2021)
Objective: Phase 3 IKEMA study (NCT03275285) showed significant improvement in PFS with Isatuximab (Isa) + carfilzomib (K) and dexamethasone (d) vs Kd in patients (pts) with relapsed multiple myeloma (MM) (HR: 0.531; 99% CI: 0.32–0.89; P=0.0007), l
Externí odkaz:
https://doaj.org/article/3c2d6faeced74604914a15ac633f598e
Autor:
Thomas Martin, Meletios-Athanasios Dimopoulos, Joseph Mikhael, Kwee Yong, Marcelo Capra, Thierry Facon, Roman Hajek, Ivan Špička, Ross Baker, Kihyun Kim, Gracia Martinez, Chang-Ki Min, Ludek Pour, Xavier Leleu, Albert Oriol, Youngil Koh, Kenshi Suzuki, France Casca, Sandrine Macé, Marie-Laure Risse, Philippe Moreau
Publikováno v:
Blood Cancer Journal, Vol 13, Iss 1, Pp 1-9 (2023)
Abstract Longer-term outcomes with the anti-CD38 antibody isatuximab in combination with carfilzomib-dexamethasone (Isa-Kd) were evaluated in the randomized Phase 3 trial IKEMA (NCT03275285), in a prespecified, follow-up analysis of progression-free
Externí odkaz:
https://doaj.org/article/8e61c702b45741d49f7cd38053f87ec5
Autor:
Thierry Facon, Philippe Moreau, Ross Baker, Chang-Ki Min, Xavier Leleu, Mohamad Mohty, Lionel Karlin, Nicole M. Armstrong, Christina Tekle, Sandrine Schwab, Marie-Laure Risse, Thomas Martin
Publikováno v:
Haematologica, Vol 109, Iss 2 (2023)
Patients with multiple myeloma (MM) who experience early relapse within 12 months of therapy initiation are considered functional high-risk and represent an unmet need, needing better therapies to improve outcomes. The final IKEMA (clinicaltrials gov
Externí odkaz:
https://doaj.org/article/a859ab568ace4b82af9a728c2589dbf0
Autor:
Thierry Facon, Philippe Moreau, Ivan Špicka, Kenshi Suzuki, Kwee Yong, Joseph Mikhael, Taro Fukao, Kamlesh Bisht, Nicole Armstrong, Sandrine Macé, Marie-Laure Risse, Thomas Martin
Publikováno v:
HemaSphere, Vol 7, p e7523284 (2023)
Externí odkaz:
https://doaj.org/article/8de8d9b1e7d94d80888228070665ce02
Autor:
Philippe Moreau, Aurore Perrot, Meletios A. Dimopoulos, Thomas Martin, Thierry Facon, Marcelo Eduardo Capra, Meral Beksac, Nicole Armstrong, Franck Dubin, Sandrine Macé, Marie-Laure Risse, Christina Tekle, Zandra Klippel, Paul Richardson
Publikováno v:
HemaSphere, Vol 7, p e27700c7 (2023)
Externí odkaz:
https://doaj.org/article/a771e98472aa4c73a829578fd9de0027
Autor:
Thomas Martin, Meletios-Athanasios Dimopoulos, Joseph Mikhael, Kwee Yong, Marcelo Capra, Thierry Facon, Roman Hajek, Ivan Špička, Ross Baker, Kihyun Kim, Gracia Martinez, Chang-Ki Min, Ludek Pour, Xavier Leleu, Albert Oriol, Youngil Koh, Kenshi Suzuki, France Casca, Sandrine Macé, Marie-Laure Risse, Philippe Moreau
Publikováno v:
Blood Cancer Journal, Vol 13, Iss 1, Pp 1-1 (2023)
Externí odkaz:
https://doaj.org/article/bbebf16ae9ae4bdab06ac313f9c5c8ac
Autor:
Ozgur PEKTAS, Philippe MOREAU, Meletios-Athanasios DIMOPOULOS, Joseph MIKHAEL, Kwee YONG, Marcelo CAPRA, Thierry FACON, Roman HAJEK, Ivan ŠPIČKA, France CASCA, Sandrine MACÉ, Marie-Laure RISSE, Thomas MARTIN
Publikováno v:
Hematology, Transfusion and Cell Therapy, Vol 44, Iss , Pp S15- (2022)
Objective: The anti-CD38 antibody Isa in combination with Kd is approved in various countries for patients (pts) with relapsed MM after ≥1 prior therapy, based on primary interim analysis (IA) of the Phase 3 IKEMA study (NCT03275285). Here we repor
Externí odkaz:
https://doaj.org/article/1fe3693b55234776bd5d8943e77e33f2
Autor:
Marcelo Capra, Thomas Martin, Philippe Moreau, Ross Baker, Ludek Pour, Chang-Ki Min, Xavier Leleu, Mohamad Mohty, Marta Reinoso Segura, Mehmet Turgut, Richard LeBlanc, Marie-Laure Risse, Laure Malinge, Sandrine Schwab, Meletios Dimopoulos
Publikováno v:
Haematologica, Vol 107, Iss 6 (2021)
Renal impairment (RI) is common in patients with multiple myeloma (MM) and new therapies that can improve renal function are needed. The phase III IKEMA study (clinicaltrials gov. Identifier: NCT03275285) investigated isatuximab (Isa) with carfilzomi
Externí odkaz:
https://doaj.org/article/07fc5002e7574551bc21eb0eddf6cde5
Autor:
Thomas Martin, Joseph Mikhael, Roman Hajek, Kihyun Kim, Kenshi Suzuki, Cyrille Hulin, Mamta Garg, Hang Quach, Hanlon Sia, Anup George, Tatiana Konstantinova, Marie-Laure Risse, Gaelle Asset, Sandrine Macé, Helgi van de Velde, Philippe Moreau
Publikováno v:
Blood Advances. 6:4506-4515
The IKEMA study (Randomized, Open Label, Multicenter Study Assessing the Clinical Benefit of Isatuximab Combined With Carfilzomib [Kyprolis®] and Dexamethasone Versus Carfilzomib With Dexamethasone in Patients With Relapse and/or Refractory Multiple
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6416388ee2b8971352d289622500df15
https://doi.org/10.1182/bloodadvances.2021006713
https://doi.org/10.1182/bloodadvances.2021006713
Autor:
Thierry Facon, Philippe Moreau, Ross Baker, Ludek Pour, Chang-Ki Min, Xavier Leleu, Mohamad Mohty, Lionel Karlin, Andreea Rawlings, Christina Tekle, Sandrine Schwab, Marie-Laure Risse, Thomas Martin
Publikováno v:
Blood. 140:1820-1822
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6da000a811bea8987a96e89289c2f1f3
https://doi.org/10.1182/blood-2022-159105
https://doi.org/10.1182/blood-2022-159105